Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert Sidbury is active.

Publication


Featured researches published by Robert Sidbury.


Journal of The American Academy of Dermatology | 2014

Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.

Lawrence F. Eichenfield; Wynnis L. Tom; Timothy G. Berger; Alfons Krol; Amy S. Paller; Kathryn Schwarzenberger; James N. Bergman; Sarah L. Chamlin; David E. Cohen; Kevin D. Cooper; Kelly M. Cordoro; Dawn Marie R. Davis; Steven R. Feldman; Jon M. Hanifin; David J. Margolis; Robert A. Silverman; Eric L. Simpson; Hywel C. Williams; Craig A. Elmets; Julie Block; Christopher G. Harrod; Wendy Smith Begolka; Robert Sidbury

Atopic dermatitis is a common and chronic, pruritic inflammatory skin condition that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this second of 4 sections, treatment of atopic dermatitis with nonpharmacologic interventions and pharmacologic topical therapies are reviewed. Where possible, suggestions on dosing and monitoring are given based on available evidence.


Pediatrics | 2013

Initiation and Use of Propranolol for Infantile Hemangioma: Report of a Consensus Conference

Beth A. Drolet; Peter C. Frommelt; Sarah L. Chamlin; Anita N. Haggstrom; Nancy M. Bauman; Yvonne E. Chiu; Robert H. Chun; Maria C. Garzon; Kristen E. Holland; Leonardo Liberman; Susan MacLellan-Tobert; Anthony J. Mancini; Denise W. Metry; Katherine B. Puttgen; Marcia Seefeldt; Robert Sidbury; Kendra M. Ward; Francine Blei; Eulalia Baselga; Laura D. Cassidy; David H. Darrow; Shawna Joachim; Eun Kyung M Kwon; Kari Martin; Jonathan A. Perkins; Dawn H. Siegel; Robert J. Boucek; Ilona J. Frieden

Infantile hemangiomas (IHs) are common neoplasms composed of proliferating endothelial-like cells. Despite the relative frequency of IH and the potential severity of complications, there are currently no uniform guidelines for treatment. Although propranolol has rapidly been adopted, there is significant uncertainty and divergence of opinion regarding safety monitoring, dose escalation, and its use in PHACE syndrome (PHACE = posterior fossa, hemangioma, arterial lesions, cardiac abnormalities, eye abnormalities; a cutaneous neurovascular syndrome characterized by large, segmental hemangiomas of the head and neck along with congenital anomalies of the brain, heart, eyes and/or chest wall). A consensus conference was held on December 9, 2011. The multidisciplinary team reviewed existing data on the pharmacologic properties of propranolol and all published reports pertaining to the use of propranolol in pediatric patients. Workgroups were assigned specific topics to propose protocols on the following subjects: contraindications, special populations, pretreatment evaluation, dose escalation, and monitoring. Consensus protocols were recorded during the meeting and refined after the meeting. When appropriate, protocol clarifications and revision were made and agreed upon by the group via teleconference. Because of the absence of high-quality clinical research data, evidence-based recommendations are not possible at present. However, the team agreed on a number of recommendations that arose from a review of existing evidence, including when to treat complicated IH; contraindications and pretreatment evaluation protocols; propranolol use in PHACE syndrome; formulation, target dose, and frequency of propranolol; initiation of propranolol in infants; cardiovascular monitoring; ongoing monitoring; and prevention of hypoglycemia. Where there was considerable controversy, the more conservative approach was selected. We acknowledge that the recommendations are conservative in nature and anticipate that they will be revised as more data are made available.


Journal of The American Academy of Dermatology | 2014

Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents

Robert Sidbury; Dawn Marie R. Davis; David E. Cohen; Kelly M. Cordoro; Timothy G. Berger; James N. Bergman; Sarah L. Chamlin; Kevin D. Cooper; Steven R. Feldman; Jon M. Hanifin; Alfons Krol; David J. Margolis; Amy S. Paller; Kathryn Schwarzenberger; Robert A. Silverman; Eric L. Simpson; Wynnis L. Tom; Hywel C. Williams; Craig A. Elmets; Julie Block; Christopher G. Harrod; Wendy Smith Begolka; Lawrence F. Eichenfield

Atopic dermatitis is a chronic, pruritic inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in atopic dermatitis management and care, providing recommendations based on the available evidence. In this third of 4 sections, treatment of atopic dermatitis with phototherapy and systemic immunomodulators, antimicrobials, and antihistamines is reviewed, including indications for use and the risk-benefit profile of each treatment option.


British Journal of Dermatology | 2008

Randomized controlled trial of vitamin D supplementation for winter‐related atopic dermatitis in Boston: a pilot study

Robert Sidbury; Ashley F. Sullivan; Ravi Thadhani; Carlos A. Camargo

which is much higher than in healthy controls (Table 2). However, the other 57Æ5% of patients with GAE did not have ichthyosis, suggesting that other factors must be studied further. Atopic diathesis is associated with dry skin; however, our results did not show a higher percentage of patients with atopic diathesis in the GAE group (Table 2). In contrast to reports in the literature, the GAE group in our study contained more women than men. The gender difference in sebaceous activity, with a rapid decline of sebaceous activity in older woman, cannot completely explain this, because half of our patients were between 21 and 40 years, and 80% of those were female. The bathing habits of women were similar to those of men (Tables 1 and 2). The significance of these results needs to be studied further.


Journal of The American Academy of Dermatology | 2014

Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches

Robert Sidbury; Wynnis L. Tom; James N. Bergman; Kevin D. Cooper; Robert A. Silverman; Timothy G. Berger; Sarah L. Chamlin; David E. Cohen; Kelly M. Cordoro; Dawn Marie R. Davis; Steven R. Feldman; Jon M. Hanifin; Alfons Krol; David J. Margolis; Amy S. Paller; Kathryn Schwarzenberger; Eric L. Simpson; Hywel C. Williams; Craig A. Elmets; Julie Block; Christopher G. Harrod; Wendy Smith Begolka; Lawrence F. Eichenfield

Atopic dermatitis is a common, chronic inflammatory dermatosis that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this final section, treatments for flare prevention and adjunctive and complementary therapies and approaches are reviewed. Suggestions on use are given based on available evidence.


The Journal of Allergy and Clinical Immunology | 2014

Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children

Carlos A. Camargo; Davaasambuu Ganmaa; Robert Sidbury; Kh. Erdenedelger; N. Radnaakhand; B. Khandsuren

BACKGROUND Epidemiologic and preclinical data, and a small randomized trial in Boston, suggest that vitamin D supplementation may improve winter-related atopic dermatitis (AD). OBJECTIVE To determine the effect of vitamin D supplementation on winter-related AD. METHODS We performed a randomized, double-blind, placebo-controlled trial of Mongolian children with winter-related AD (clinicaltrials.gov identifier: NCT00879424). Baseline eligibility included age 2 to 17 years, AD score 10 to 72 using the Eczema Area and Severity Index (EASI), and winter-related AD (eg, history of AD worsening during the fall-to-winter transition). Subjects were enrolled in Ulaanbaatar during winter and randomly assigned to oral cholecalciferol (1000 IU/day) versus placebo for 1 month. All children and parents received emollient and patient education about AD and basic skin care. The main outcomes were changes in EASI score and in Investigators Global Assessment. RESULTS The 107 enrolled children had a mean age of 9 years (SD 5), and 59% were male. Their median age of AD onset was 3 months (interquartile range 2 months to 1 year) and mean EASI score at baseline 21 (SD 9). One-month follow-up data were available for 104 (97%) children. Compared with placebo, vitamin D supplementation for 1 month produced a clinically and statistically significant improvement in EASI score (adjusted mean change: -6.5 vs -3.3, respectively; P = .04). Moreover, change in Investigators Global Assessment favored vitamin D over placebo (P = .03). There were no adverse effects in either group. CONCLUSION Vitamin D supplementation improved winter-related AD among Mongolian children, a population likely to have vitamin D deficiency in winter.


Current Opinion in Pediatrics | 2006

Cutaneous manifestations of nutritional deficiency

Michelle L. Heath; Robert Sidbury

Purpose of review Nutritional deficiency, a global problem, remains uncommon in developed nations. Associated morbidity and mortality make it imperative that clinicians remain familiar with the clinical signs and symptoms of nutritional deficiencies to facilitate diagnosis. This article will review the cutaneous findings and recent literature regarding B12, niacin, zinc, vitamin A, kwashiorkor, biotin and selenium deficiencies, along with the clinical entities of noma and phrynoderma. Recent findings Much of our understanding of the clinical manifestations of nutritional deficiencies comes from old literature; however, recent case reports and series have highlighted several patient populations that may be at risk from acquired deficiencies, including patients with anorexia nervosa, cystic fibrosis, patients receiving long-term tube-feeding and those with perceived or real food allergy. There can be significant clinical overlap between various micronutrient, protein and vitamin deficiencies. Additionally, providers should consider the possibility of multiple deficiencies coexisting in individual patients. Summary Reports of nutritional deficiency continue to surface in developed nations and pediatricians need to have a basic understanding of their clinical manifestations. The skin is commonly affected and can be the presenting sign of illness. A higher clinical suspicion needs to be maintained in certain populations.


Otolaryngology-Head and Neck Surgery | 2011

Initial Experience With a Multidisciplinary Strategy for Initiation of Propranolol Therapy for Infantile Hemangiomas

Sharon L. Cushing; Robert J. Boucek; Scott C. Manning; Robert Sidbury; Jonathan A. Perkins

Objectives. To outline a safe, standardized protocol for outpatient initiation of propranolol therapy for infantile hemangiomas. Study Design. Retrospective review. Setting. Academic tertiary care pediatric hospital. Subjects and Methods. Forty-nine infantile hemangioma patients were offered propranolol therapy and included in the study. Any patients requiring hospital admission were excluded. Screening consisted of cardiology evaluation, including electrocardiography and, when indicated, echocardiography. Target initiation dose was 2 to 3 mg/kg/d divided into 3 doses. Blood pressure and heart rate were initially monitored at baseline and 1 and 2 hours in clinic following initial dosing. A 3-hour time point was later added. Families received standardized instructions regarding home heart rate monitoring, side effects, and fasting. Results. Outpatient propranolol therapy was safely initiated in 39 of 44 patients (89%). Five patients required brief admission: 1 with clinical signs/symptoms of heart failure, 3 having airway involvement, and 1 for social reasons. Propranolol administration transiently reduced blood pressure; the maximal decrease occurred at 2 hours, prompting addition of a 3-hour time point to ensure recovery. No patients exhibited symptomatic hypotension, bradycardia, or heart failure. Conclusions. In most children with infantile hemangiomas, propranolol therapy can be safely initiated as an outpatient. Careful cardiovascular evaluation by an experienced clinician is essential for pretreatment evaluation, inpatient admission (when necessary), blood pressure and heart rate monitoring following initial dosing, and parent education. This standardized multidisciplinary outpatient initiation plan reduces the cost of initiating therapy compared with inpatient strategies while still providing appropriate monitoring for potential treatment complications. Further evaluation of propranolol therapy efficacy at the current dosing and duration of treatment continues.


Current Opinion in Pediatrics | 2010

Update on vascular tumors of infancy

Robert Sidbury

Purpose of review Advances have been made in the pathogenesis, diagnosis and management of vascular tumors of infancy in the past year. Propranolol therapy for infantile hemangiomas (IH) is now being used widely, and case reports, series, and adverse effects are reviewed. Kaposiform hemangioendothelioma and tufted angioma are less common than IH but more often associated with coagulopathy (Kasabach–Merritt phenomenon). Recent findings Recent work suggests that stem cells, mediated by the Notch signaling pathway, may become proliferating endothelial cells that comprise IH. Large, segmental IH are more likely to develop complications that can include life-threatening bleeds; however, solitary large IH do not appear to increase the risk of hepatic IH. Segmental IH may herald underlying structural anomalies of the brain, cerebral, and cardiac vessels (PHACE syndrome– Posterior fossa defects, Hemangiomas, Arterial anomalies, Cardiac defects and Coarctation of the aorta, Eye anomalies), and new criteria aid in diagnosis. Propranolol therapy is effective in life-threatening IH and appears to stop growth and hasten involution in proliferative and plateau phase IH. Adverse effects include bradycardia, hypotension, hypoglycemia, and bronchospasm. A recent review of kaposiform hemangioendothelioma finds that an associated coagulopathy (Kasabach–Merritt phenomenon) occurs in 72%. Summary Propranolol appears to be tremendously efficacious with fewer side effects than systemic corticosteroids, but its proper place in the therapeutic algorithm for IH and other vascular tumors awaits controlled study.


Journal of The American Academy of Dermatology | 2008

Pediatric dermatology workforce shortage: Perspectives from academia

Brittany G. Craiglow; Jack S. Resneck; Anne W. Lucky; Robert Sidbury; Albert C. Yan; Steven D. Resnick; Richard J. Antaya

BACKGROUND The pediatric dermatology workforce has not been systematically evaluated since recent changes in board certification requirements. OBJECTIVE To quantify and characterize the workforce of academic pediatric dermatologists and examine issues related to training, hiring, and retention. METHODS Dermatology chairpersons and residency directors in the United States and Canada completed a 30-question survey. RESULTS Eighty of 132 programs (61%) responded to the survey. More than two thirds of programs (56/80) employed a pediatric dermatologist, and 34 programs were recruiting a pediatric dermatologist. The number of residents that pursue careers in pediatric dermatology is significantly associated with the number of pediatric dermatologists on faculty at their institution. LIMITATIONS Self-reported data, which may have been reflected by recall bias, and 61% response rate. CONCLUSIONS At a majority of academic centers, the current pool of pediatric dermatology faculty is neither adequate to meet academic nor clinical demands. Methods to increase exposure to pediatric dermatology among medical students and residents must be sought.

Collaboration


Dive into the Robert Sidbury's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Julie Block

Rafael Advanced Defense Systems

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert G. Phelps

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Wynnis L. Tom

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge